Skip to Content

Immunotherapy + Chemoradiotherapy Could Lead to More Effective Treatment of Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Dr. Xuefeng Leng from Sichuan Cancer, Hospital & Institute located in Chengdu, China present in this MEDtalks the results from his late breaking abstract presented at ACCO GI 2025. This is the first three-arm randomized trial to evaluate immunotherapy-based combination treatment modalities against a standard neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma.
In the MEDtalk Dr. Xuefeng Leng emphasize that the results of the study show that immunotherapy + chemoradiotherapy could lead to more effective treatment of resectable locally advanced esophageal squamous cell carcinoma.

Xuefeng Leng

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top